Syntimmune Turns Drug For Rare Anemia Into $400M Alexion Buyout | Enterpreneurship

0
Want create site? Find Free WordPress Themes and plugins.

Want create site? Find Free WordPress Themes and plugins.

, a biotech startup formed by the veteran founders of the hemophilia developer Syntonix, has been acquired by Pharmaceuticals for $400 million in cash up front.

Syntimmune is right in Alexion’s (NASDAQ: ALXN) wheelhouse. The Boston-based firm is best known for eculizumab (Soliris), a drug for ultra- blood diseases. In buying Syntimmune, Alexion will acquire an experimental drug for a type of , warm autoimmune hemolytic (WAIHA). Beyond the upfront cash, Syntimmune’s shareholders, led by Apple Tree Partners, could see another $800 million in downstream payments if the drug progresses.

Syntimmune was formed in 2013 by… Read more »


UNDERWRITERS AND PARTNERS


Did you find apk for android? You can find new Free Android Games and apps.
Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.